Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Consolidation therapy in ovarian cancer: a clinical update.

Sabbatini P.

Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S35-9. doi: 10.1111/IGC.0b013e3181c14007. Review.

PMID:
19955912
[PubMed - indexed for MEDLINE]
2.

Detecting an overall survival benefit that is derived from progression-free survival.

Broglio KR, Berry DA.

J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9. doi: 10.1093/jnci/djp369. Epub 2009 Nov 9.

PMID:
19903805
[PubMed - indexed for MEDLINE]
Free Article
3.

Consolidation strategies in ovarian cancer: observations for future clinical trials.

Sabbatini P, Spriggs D, Aghajanian C, Hensley M, Tew W, Konner J, Bell-McGuinn K, Juretzka M, Iasonos A.

Gynecol Oncol. 2010 Jan;116(1):66-71. doi: 10.1016/j.ygyno.2009.09.016.

PMID:
19836827
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A review of the current evidence for maintenance therapy in ovarian cancer.

Foster T, Brown TM, Chang J, Menssen HD, Blieden MB, Herzog TJ.

Gynecol Oncol. 2009 Nov;115(2):290-301. doi: 10.1016/j.ygyno.2009.07.026. Epub 2009 Aug 31. Review.

PMID:
19717182
[PubMed - indexed for MEDLINE]
5.

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D.

Gynecol Oncol. 2009 Aug;114(2):195-8. doi: 10.1016/j.ygyno.2009.04.012. Epub 2009 May 17.

PMID:
19447479
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.

Juretzka M, Hensley ML, Tew W, Konner J, Aghajanian C, Leitao M, Iasonos A, Soslow R, Park K, Sabbatini P.

Eur J Gynaecol Oncol. 2008;29(6):568-72.

PMID:
19115680
[PubMed - indexed for MEDLINE]
7.

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.

Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF.

J Clin Oncol. 2009 Jan 20;27(3):418-25. doi: 10.1200/JCO.2008.17.8400. Epub 2008 Dec 15.

PMID:
19075271
[PubMed - indexed for MEDLINE]
8.

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R.

Gynecol Oncol. 2007 Nov;107(2):173-6.

PMID:
17950384
[PubMed - indexed for MEDLINE]
9.

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P.

Cancer. 2007 Dec 1;110(11):2448-56.

PMID:
17918264
[PubMed - indexed for MEDLINE]
Free Article
10.

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P.

Gynecol Oncol. 2007 Sep;106(3):469-75. Epub 2007 Jul 5.

PMID:
17614127
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Consolidation therapy in ovarian cancer: where do we stand?

Dearnley DD, McMeekin DS.

Curr Opin Obstet Gynecol. 2006 Feb;18(1):3-7. Review.

PMID:
16493252
[PubMed - indexed for MEDLINE]
12.

Consolidation for ovarian cancer in remission.

Sabbatini P, Spriggs DR.

J Clin Oncol. 2006 Feb 1;24(4):537-9. No abstract available.

PMID:
16446325
[PubMed - indexed for MEDLINE]
13.

Design issues of randomized phase II trials and a proposal for phase II screening trials.

Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA.

J Clin Oncol. 2005 Oct 1;23(28):7199-206.

PMID:
16192604
[PubMed - indexed for MEDLINE]
14.

Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.

Gadducci A, Cosio S, Conte PF, Genazzani AR.

Crit Rev Oncol Hematol. 2005 Aug;55(2):153-66. Review.

PMID:
15890524
[PubMed - indexed for MEDLINE]
15.

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J.

J Clin Oncol. 2004 Aug 1;22(15):3120-5.

PMID:
15284263
[PubMed - indexed for MEDLINE]
16.

Natural history of stage IV epithelial ovarian cancer.

Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, Shepherd JH, Gore ME.

J Clin Oncol. 1999 Mar;17(3):767-75.

PMID:
10071265
[PubMed - indexed for MEDLINE]
17.

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M.

N Engl J Med. 1996 Jan 4;334(1):1-6.

PMID:
7494563
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk